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Abstract
The antioxidant peroxiredoxin (PRDX) protein family comprises 6 members, which are implicated in a variety of cellular
responses, including growth factor signal transduction. PRDX4 resides in the endoplasmic reticulum (ER), where it locally
controls oxidative stress by reducing H2O2 levels. We recently provided evidence for a regulatory function of PRDX4 in signal
transduction from a myeloid growth factor receptor, the granulocyte colony-stimulating factor receptor (G-CSFR). Upon
activation, the ligand-induced G-CSFR undergoes endocytosis and routes via the early endosomes where it physically
interacts with ER-resident PRDX4. PRDX4 negatively regulates G-CSFR mediated signaling. Here, we investigated whether
PRDX4 is affected in acute myeloid leukemia (AML); genomic alterations and expression levels of PRDX4 were investigated.
We show that genomic abnormalities involving PRDX4 are rare in AML. However, we find a strong reduction in PRDX4
expression levels in acute promyelocytic leukemia (APL) compared to normal promyelocytes and different molecular
subtypes of AML. Subsequently, the possible role of DNA methylation and histone modifications in silencing of PRDX4 in
APLs was investigated. We show that the reduced expression is not due to methylation of the CpG island in the promoter
region of PRDX4 but correlates with increased trimethylation of histone 3 lysine residue 27 (H3K27me3) and lysine residue 4
(H3K4me3) at the transcriptional start site (TSS) of PRDX4, indicative of a bivalent histone code involved in transcriptional
silencing. These findings suggest that the control of G-CSF responses by the antioxidant protein PRDX4 may be perturbed in
APL.
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Introduction
G-CSF induces the proliferation, survival and neutrophilic
differentiation of myeloid progenitor cells [1]. This response
depends on the balanced activation and subsequent attenuation
of signaling pathways linked to the G-CSFR, which is to a major
extent controlled by lysosomal routing of the activated G-CSFR
complex [2,3]. Signal attenuation of the G-CSFR is compro-
mised by mutations causing truncations in the cytoplasmic
domain of the receptor, found in severe congenital neutropenia
(SCN) patients showing disease progression to acute myeloid
leukemia (AML) [4,5,6]. These truncated G-CSFR forms are
defective in internalization and lysosomal routing, which plays a
major role in the abnormal signaling function of these receptor
mutants.
Another important feature of the G-CSFR truncation mutants is
that their activation results in elevated levels of reactive oxygen
species(ROS) relativetothe wild typeG-CSFR[7]. ROS havebeen
shown to modulate growth factor signal transduction, due to
inactivation of oxidation sensitive protein and lipid phosphatases
[8,9]. Increased concentrations of intracellular ROS, however, have
been implicated in DNA damage as well as in damage to proteins
and lipids. Hence it is of importance to maintain steady state levels
of ROS. PRDX4 is an antioxidant protein which resides in the
endoplasmic reticulum. It is not only responsible for maintaining
steady state levels of ROS but also for reactivation of oxidized
phosphatases [10,11]. Our recent findings suggest that PRDX4
interacts with a C-terminal region of the G-CSFR, a region lacking
inthe truncated G-CSFRfound inSCN/AML. PRDX4 wasshown
to attenuate G-CSFR signaling dependent on the integrity of its
redox active thiol group (Palande et al, manuscript submitted).
Supporting a possible involvement of PRDX4 in leukemogenesis, a
chromosomal translocation, t(X;21)(p22;q22) has been reported in a
case of AML resulting in a PRDX4-RUNX1 fusion transcript [12].
We have investigated whether the PRDX4 locus is associated
with translocations and mutations in AML and whether its
expression levels are altered. We report that chromosomal
translocations involving the PRDX4 locus are rare in AML. In
addition, we did not detect single nucleotide variations in the
PRDX4 coding region in a large panel of AML and MDS patients.
On the other hand, we found that PRDX4 expression is
significantly decreased in APL, a subset of leukemias that is
characterized by hyper responsiveness to G-CSF [13]. Reduced
PRDX4 expression in APL is associated with a bivalent histone
methylation mark, i.e., the combination of repressive histone
methylation mark H3K27me3 and the activating histone meth-
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methylation of CpG islands in its promoter region.
Results
Genetic abnormalities affecting the PRDX4 coding region
are rare in MDS and AML
Previously, a case of AML with a t(X;21)(p22;q22) has been
reported in which the PRDX4 gene located on Xp22 was fused to
RUNX1 at 21q22, resulting in a RUNX1-PRDX4 fusion transcript
[12]. In a cohort of AML and MDS patients karyotypically
analyzed in our institution between 1990 and 2008, we found 9
cases with chromosomal abnormalities involving Xp21/p22 by
standard banding techniques. These cases were further studied for
possible rearrangements in the PRDX4 locus using FISH with a
PRDX4 break apart probeset, but no translocations, deletions or
other gross rearrangements were detected. Subsequently, we
screened cDNA from 65 MDS patients and 113 AML patients for
possible mutations or polymorphisms, but no mutations in the
PRDX4 coding region were detected in these samples. Thus, our
data confirms that genomic aberrations affecting the PRDX4
coding region are rare in MDS/AML and so far confined to the
one reported case [12].
PRDX4 is down regulated in APL
Next, we analyzed PRDX4 expression levels in 461 myeloid
leukemia patients measured on gene expression arrays [14]. In the
majority of APL patients, PRDX4 levels are below detection
levels; on average, PRDX4 transcript levels were 4 to 5 times lower
in APL, relative to other AML samples (Figure 1A and 1B). In
contrast, expression of the other PRDX family members were not
(PRDX1, 2, 5 and 6) or only marginally (PRDX3) reduced in the
APL patient cluster (Figure 1A and B). A recent study showed that
TNFa-related Apoptosis Inducing Ligand (TRAIL) suppresses the
expression of PRDX4 [15]. We therefore first investigated whether
low levels of PRDX4 expression in APL are associated with high
expression of TRAIL, but we did not find evidence for such an
inverse correlation (Pearson correlation coefficient 0.26–0.35 for 3
different TRAIL probe set comparisons, data not shown). Western
blot analysis showed that the PRDX4 protein, while readily
detectable in AML blast cells with high transcript levels, is low/
undetectable in APL cells correlating with the gene expression
profiling data (Figure 2A). In contrast, PRDX4 protein levels were
not reduced in normal bone marrow-derived myeloblasts,
promyelocytes and myelocytes (Figure 2B, upper panel), suggesting
that the down regulation of PRDX4 is specific for leukemic
promyelocytes. The purity of the sorted fractions of cells used for
Western blotting as mentioned above was assessed using cytospins
of the individual fractions stained with May GrU ¨nwald Giemsa
(Figure 2B, lower panel).
Reduced PRDX4 expression in APL is not due to DNA
methylation of CpG islands in the PRDX4 promoter
PML-RARa recruits DNA methyltransferases such as DNMT1
and DNMT3a and is thereby potentially able to methylate CpG
islands in target genes, leading to transcriptional silencing [16].
We asked whether PRDX4 expression in APLs might be silenced
by DNA methylation. Because PRDX4 is located on the X
chromosome, one allele is methylated in female cells. CpG
methylation on both alleles in female samples or on one allele in
the male APL samples was not observed (data not shown). Thus,
no evidence was obtained indicating that DNA methylation of
CpG islands within the promoter region contributes to silencing of
PRDX4 in APL cells.
APL cells have increased levels of H3K27me3 and
H3K4me3 at the TSS of PRDX4
PML-RARa recruits the polycomb repressor complex 2 (PRC2)
that contains EZH2 as a major effector protein [17]. EZH2
represses gene expression through H3K27me3, leading to an
inactive chromatin configuration [18]. ChIPs performed on
primary APL cells showed an increased occupation of
H3K27me3 at the TSS of PRDX4 (Figure 3A), which was not
observed in AML samples expressing PRDX4. Unlike the
H3K27me3 ChIPs, results from H3K4me3 ChIPs showed
occupation of the TSS of PRDX4 by the H3K4me3 methylation
mark in both, APLs as well as AMLs (Figure 3B).
Discussion
The major finding reported here is that expression of the
antioxidant protein PRDX4 is repressed in t(15;17) APL harboring
the PML-RARa fusion protein. Our data indicate that transcrip-
tional regulation of PRDX4 is perturbed in APLs because normal
promyelocytes do not show reduced PRDX4 protein levels. This
reduced expression is linked to a bivalent histone mark, i.e.,
increased H3K27me3 and H3K4me3, at the TSS of PRDX4.
Bivalent histone marks provide a switch mechanism shown to be
involved in transcriptional regulation of developmental genes; loss
of the H3K27me3 mark leads to transcriptional activation whereas
loss of H3K4me3 results in permanent silencing [19]. Our data
suggest that reduced PRDX4 expression in APLs is caused by
maintenance of H3K27me3, which perturbs the bivalent switch.
We hypothesized that PML-RARa might be involved in
repressing PRDX4 expression, especially because PML-RARa
recruits the polycomb repressor complex (PRC2) that contains the
histone methyltransferase EZH2 responsible for H3K27me3 [17].
Wild type retinoic acid receptors (RARs) are known to bind to
specific DNA sequences called RA responsive elements (RAREs)
and are able to repress transcription by recruiting co-repressor
complexes such as SMRT/NCoR/HDAC [20]. The promoter
region of PRDX4 however does not contain any retinoic acid
responsive element (RARE) that may be bound by RARa/RXR
directly. Another mechanism shown to be involved in suppression
of genes via PML-RARa is the modulation of the activity of Sp1
target genes via binding to the transcription factor Sp1 [21]. Six
Sp1 sites are present within the region of 21k bt o+1 kb of the
TSS of PRDX4, to which the PML-RARa fusion protein may bind
in a RARE independent manner [21].
To support the hypothesis of PML-RARa-mediated recruit-
ment of PRC2/EZH2 to the PRDX4 TSS, leading to H3K27me3
repression of the gene, we have attempted to restore PRDX4
expression in primary APL. To achieve this, APL cells were
incubated with (combinations of) pharmacological compounds
that included the ‘‘de-repressing’’ agents ATRA, the histone
deacetylase inhibitor valproic acid and EZH2 inhibitor DZNep,
which reduces EZH2 protein levels and thereby the level of
H3K27me3 at transcriptional start sites of certain genes [22].
However, down regulation of EZH2 by DZNep, as previously
shown by Jiang et al in colorectal cancer cells, was not seen in the
APL samples used in our studies. Further studies are required to
support a direct involvement of PML-RARa in PRDX4 down
regulation.
Irrespective of the molecular mechanism of transcriptional
silencing, a lack of PRDX4 may have a major impact on cellular
responses of myeloid cells and contribute to leukemogenesis.
PRDX4 resides mainly in the endoplasmic reticulum (ER), where
it is thought to neutralize the oxidizing effects of locally produced
ROS [23]. This would keep for instance oxidation sensitive ER-
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(PTP1B), in an active state. PTP1B has been shown to play a role
in down modulation of G-CSFR mediated signaling by dephos-
phorylating JAK2, STAT3 and the tyrosines of the G-CSFR
(Palande et al, manuscript submitted). Predictably, loss of PRDX4
could lead to a reduction of phosphatase activity, providing an
explanation for the increased responsiveness of APL clonogenic
precursors to G-CSF.
Materials and Methods
Human cell samples
All human cell samples were obtained after written informed
consent and stored anonymously in a biobank. The study was
performed under the permission of the Institutional Review Board
of the Erasmus MC, registration number MEC-2008-387.
Preparation of leukemia cell samples has been described previously
[24]. Normal myeloblasts, promyelocytes and neutrophils were
isolated from normal bone marrow samples using fluorescence
activated cell sorting (FACS). Erythrocytes were removed prior to
FACS sorting, by hypotonic lysis (15 min.), followed by a wash
with phosphate buffer saline (PBS). The cells were then
resuspended in PBS and incubated with fluorescent dye conjugat-
ed antibodies CD10-APC, CD11b-APC-Cy7, CD34-Pe-Cy7 and
CD117-PE (Becton Dickinson, NJ) dead cells were excluded using
a combination of forward and side scatter and DAPI staining.
Cells were sorted with a FACSAria (Becton Dickinson, Becton
Dickinson and Company, NJ) on the following criteria: CD342
and CD117+ for promyelocytes; CD34+ and CD117+ for
myeloblasts; CD10+ and CD11b+ for neutrophils.
Mutation analysis of the PRDX4 coding region
A WAVE device (Transgenomics, Omaha, NE, USA) was used
to screen for mutations in the PRDX4 coding region. cDNA from
113 AML and 65 MDS patients was analyzed. The coding region
of PRDX4 was PCR amplified in 4 separate parts, the length of
each part being approximately 300 base pairs with an overlap of at
least 60 base pairs between two consecutive fragments. The first
part of the PCR was amplified using primers PRDX4 F1 (59-
CCAAGGGACGTGTTTCTGCG-39) and primer PRDX4 R1
WAVE (59-CTGGCTTGGAAATCTTCGC-39). The second part
was amplified using primers PRDX4 F2 WAVE (59-GAGGAG-
TGCCACTTCTACGCG-39) and PRDX4 R2 WAVE (59-CTG-
TGAATCAACAGAGCATG-39). The third part of PRDX4 was
amplified using primers PRDX4 F3 WAVE (59-GGTTTT-
CTTCTTCTACCCACT-39) and PRDX4 R3 WAVE (59-CATT-
CAGAGTAATTTGTCTTAG-39). The last part of PRDX4 was
amplified using primers PRDX4 F4 WAVE (59-GGAC-
Figure 1. Expression of PRDX transcripts in AML and APL. A. Graphical representation of expression of PRDX family members in APL patients
clustered based on expression of ,2000 genes as described [24]. Cluster 12 is exclusively formed by APL patients, as indicated by the red
bars indicating the presence of t(15;17). Cluster 11 comprises AML patients with normal karyotype and an underlying NPM1 mutation. Cluster 13 is
formed by AML patients with t(8;21). Histograms represent MAS5-normalized expression values. B. Expression levels of the peroxiredoxin gene family
in APL (n=22) were compared to transcript levels in AML (n=439). Significant differences were calculated using a Wilcoxon test. * = p-value ,0.001,
** = p-value ,0.0001.
doi:10.1371/journal.pone.0016340.g001
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ACTTTATTGAGAACTTTC-39).
FISH analysis
A locus-specific break apart FISH probeset was designed using
the BAC clones CTD-2114P24 (chrX: 23457583- 23659210) and
CTD-2594J24 (chrX:23638596-23807502). Clone isolation and
labeling were performed using biotin-16-dUTP and digoxigenin-
11-dUTP (Roche Diagnostics Belgium, Vilvoorde, Belgium)
according to the manufacturer’s protocol. The FISH analysis
was performed as previously described on metaphase preparations.
For this, patient samples were cultured and harvested according to
standard cytogenetic protocols. Hybridized preparations were
digitally imaged and analyzed using Isis (MetaSystems, Altlus-
sheim, Germany). A minimum of 100 interphase nuclei and 5
metaphases were analyzed [25].
Gene expression analysis
To determine expression of different peroxiredoxin family
members (PRDX1-6), data of 439 de novo AML and 22 APL
samples were used [14]. For each gene, probe sets were
determined and the average expression levels in AML and APL
were calculated. Significant differences within these two groups
were determined with a Wilcoxon test. Multiple testing correction
was performed using the Benjamini-Hochberg algorithm. Probe-
sets with an FDR below 0.05 were considered to be differentially
expressed in APL compared to AML. To examine a possible
inverse correlation between expression of PRDX4 and TRAIL,
Pearson correlation coefficients were calculated separately in the
APL cases.
Western blotting and antibodies
Cells were lysed in lysis buffer (20 mM Tris HCl pH 8.0,
137 mM NaCl, 10 mM EDTA, 100 mM NaF, 1% NP40, 10%
glycerol, 2 mM Na3VO4 and 1 mM Pefablock SC). SDS-
polyacrylamide gel electrophoresis was performed using precast
4–12% bis-Tris gradient gels (Invitrogen, Breda, the Netherlands).
Prdx4 mouse monoclonal antibody was purchased from Abcam,
(Cambridge, UK), b-actin antibody from Santa Cruz Biotechnol-
ogy Inc. (Santa Cruz, CA).
Bisulfite sequencing
Bisulfite treatment of genomic DNA from APL or AML samples
was performed using the EpiTect bisulphite kit (Qiagen, Hilden,
Germany). PCR was performed on bisulfite treated DNA using
methylation insensitive primers PRDX4 bisulfite seq Fw1 (59-TT-
GTTTTTATAGAGTTGGGTAA-39) and PRDX4 bisulfite seq
Rv1 (59-AAACCTCTCCTCTATCTCC-39). A nested PCR was
performed on this PCR product using methylation insensitive
primers PRDX4 bisulfite seq Fw2 (59- TAAATGTAGGTTTGG-
GATGG-39) and PRDX4 bisulfite seq Rv2 (59- CCAACCCTA-
CACAACTCCAA-39). For sequencing, the PCR product was sub-
cloned into TA cloning vector (Invitrogen, Breda, the Nether-
lands). DNA was isolated from individual colonies and sequenced
using the M13Fw (59-GTAAAACGACGGCCAG-39) and the
M13Rv (59-CAGGAAACAGCTATGAC-39) primers.
Chromatin isolation
Ten million cells were suspended in 10 ml culture medium and
cross-linked with 1% formaldehyde for 10 min at RT. The
reaction was quenched with 130 mM glycine. Cells were washed
twice with cold PBS and subsequently incubated on ice for 10 min
with cold nuclei lysis buffer (50 mM Tris HCl, 10 mM EDTA, 1%
SDS) to which 1 mM protease inhibitors (Sigmafast, Sigma
Aldrich, St Louis, MO) and 4 mM PMSF (Sigma Aldrich, St
Louis, MO) was freshly added. Lysed cells were subjected to 6
cycles of sonication for 20 sec to obtain fragments of 200–1000 bp
(Sanyo Soniprep 150). After centrifugation (10 minutes, 10.000 g)
at 4uC to remove cell debris, the chromatin-containing superna-
tant fraction was pre-cleared by incubation with 50 mg pre-
immune serum (IgG from rabbit serum I8140, Sigma-Aldrich, St
Louis, MO) for 30 min at 4uC followed by addition of 100 ml
protein A magnetic beads (Invitrogen, Breda, the Netherlands) for
30 min at RT.
Figure 2. Reduced PRDX4 protein and transcript levels in APL. A. Lysates of APL and AML samples were analyzed for PRDX4 protein levels.
Because human PRDX4 gene is located on the X-chromosome, male samples and female samples were compared with male and female AML control
samples respectively to rule out the possibility of X-inactivation involvement. Patient number followed by F indicates female sample while patient
number followed by M indicates male sample. B. Upper panel: Western blot analysis of PRDX4 expression in different normal bone marrow fractions
(myeloblasts, promyelocytes, neutrophils). Lower panel: Micrographs of May Grunwald Giemsa stained fractions of cells used for Western blotting.
doi:10.1371/journal.pone.0016340.g002
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For immunoprecipitation, protein A dynabeads (Invitrogen,
Breda, the Netherlands) were pre-incubated with antibodies
against H3K27me3 (07-449, Upstate Biotechnology Inc, Charlot-
tesville, VA) or IgG pre-immune serum as control (Sigma Aldrich,
St Louis, MO). Twenty-five ml beads and 2.5 mg antibody were
incubated for 30 min at room temperature. Beads pre-coupled to
respective antibodies were then added to the pre-cleared
chromatin and incubated for 2 hrs at 4uC. Magnetic beads
containing the chromatin complexes were collected with a magnet
and sequentially washed (56) with 500 ml: 16 low salt wash for
1 min (20 mM Tris-HCl, 150 mM NaCl, 0.1% SDS, 1% Triton
X-100, 1 mM PMSF), 16high salt wash for 1 min (20 mM Tris-
HCl, 500 mM NaCl, 0.1% SDS, 1% Triton X-100, 2 mM
EDTA, 1 mM PMSF), 16LiCl wash for 5 min (10 mM Tris-HCl,
0.25 M LiCl, 1 mM EDTA, 1% IGEPAL, 1% deoxycholate,
1 mM PMSF) and 26 TE buffer for 1 min each (10 mM Tris
HCl, 1 mM EDTA). ChIP samples were eluted with 200 ml
Figure 3. Bivalent H3K27me3 and H3K4me3 marks are present at the TSS of PRDX4. ChIP using aH3K27me3 and an IgG control (A) and
aH3K4me3 and an IgG control (B) showing an enrichment of both H3K27me3 and H3K4me3 at the TSS of PRDX4 in APL cells. To rule out a possible
involvement of X-inactivation, and thereby H3K27me3, in silencing of PRDX4 expression, male APL samples are compared to a male AML control and
female APL samples are compared to a female AML control.
doi:10.1371/journal.pone.0016340.g003
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65uC for one hr, subsequently 3.75 mM NaCl was added and
incubated overnight at 65uC to reverse the cross-linking. After de-
cross-linking, 2.4 mg proteinase K (Roche, Basel, Switzerland) was
added for protein digestion. DNA was purified using a QIAquick
PCR purification kit (Qiagen, Hilden, Germany).
Quantitative PCR of ChIP-enriched sequences was performed
using SYBR Green PCR Master Mix (Applied Biosystems,
Weiterstadt, Germany). The MYT1 gene served as a positive
control in H3K27me3 ChIP [26]. For PRDX4, a primer set for the
predicted TSS was used: Fw (59-CAAATGCAGGCTTGG-
GATGG-39) and Rv (59-CAGCGCCTCCATGACCACG-39).
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